Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh<sup>®TM</sup>) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer

Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh<sup>®TM</sup>) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer

This analysis of the RASH trial (NCT01729481) aimed at gaining a better understanding of the “Burden of Therapy” (BOTh<sup>®TM</sup>) in pancreatic ductal adenocarcinoma (PDAC). In the RASH study, 150 patients with newly diagnosed metastatic PDAC were treated with gemcitabine plus erloti...

Full description

Bibliographic Details
Main Authors: Klara Dorman, Stefan Boeck, Robert J. Snijder, Jens T. Siveke, Michael Schenk, Julia Mayerle, Karel Caca, Jens Freiberg-Richter, Ludwig Fischer von Weikersthal, Frank Kullmann, Anke Reinacher-Schick, Martin Fuchs, Stephan Kanzler, Volker Kunzmann, Thomas J. Ettrich, Danmei Zhang, Swantje Held, Ayad Abdul-Ahad, Michael von Bergwelt-Baildon, Volker Heinemann, Michael Haas
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Current Oncology
Subjects:
burden of therapy
erlotinib
FOLFIRINOX
gemcitabine
pancreatic cancer
quality of life
Online Access:https://www.mdpi.com/1718-7729/30/6/436

Internet

https://www.mdpi.com/1718-7729/30/6/436

Similar Items